Total Payments
$33,551
2024 Payments
$7,056
Companies
6
Transactions
37
Medicare Patients
738
Medicare Billing
$52,870
Payment Breakdown by Category
Research$14,890 (44.4%)
Consulting$10,361 (30.9%)
Other$6,738 (20.1%)
Travel$1,121 (3.3%)
Food & Beverage$442.24 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,890 | 12 | 44.4% |
| Consulting Fee | $10,361 | 8 | 30.9% |
| Honoraria | $6,738 | 6 | 20.1% |
| Travel and Lodging | $1,121 | 4 | 3.3% |
| Food and Beverage | $442.24 | 7 | 1.3% |
Payments by Type
General
$18,661
25 transactions
Research
$14,890
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $11,690 | 8 | $0 (2024) |
| Amylyx Pharmaceuticals, Inc. | $8,099 | 9 | $0 (2024) |
| Corcept Therapeutics | $7,956 | 5 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $3,200 | 4 | $0 (2021) |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $1,514 | 10 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $1,092 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,056 | 6 | Corcept Therapeutics ($4,869) |
| 2023 | $10,936 | 9 | Amylyx Pharmaceuticals, Inc. ($6,786) |
| 2022 | $2,000 | 2 | Biogen, Inc. ($1,050) |
| 2021 | $5,520 | 4 | Biogen, Inc. ($3,028) |
| 2020 | $5,939 | 15 | Biogen, Inc. ($2,625) |
| 2019 | $2,100 | 1 | Biogen, Inc. ($2,100) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Corcept Therapeutics | — | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| 05/09/2024 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: NEUROLOGY | ||||||
| 04/24/2024 | Corcept Therapeutics | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 03/01/2024 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Consulting Fee | Cash or cash equivalent | $787.50 | General |
| Category: NEUROLOGY | ||||||
| 02/22/2024 | Biogen, Inc. | — | — | Cash or cash equivalent | $875.00 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 01/10/2024 | Corcept Therapeutics | — | Consulting Fee | Cash or cash equivalent | $1,543.75 | General |
| 12/01/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $2,537.50 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Food and Beverage | In-kind items and services | $48.87 | General |
| Category: NEUROLOGY | ||||||
| 10/25/2023 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $2,137.50 | General |
| Category: Endocrinology | ||||||
| 09/01/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $1,312.50 | General |
| Category: NEUROLOGY | ||||||
| 08/22/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $1,575.00 | General |
| Category: NEUROLOGY | ||||||
| 07/26/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $525.00 | General |
| Category: NEUROLOGY | ||||||
| 07/25/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $525.00 | General |
| Category: NEUROLOGY | ||||||
| 07/18/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $262.50 | General |
| Category: NEUROLOGY | ||||||
| 02/16/2023 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,012.50 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 09/21/2022 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| Category: Endocrinology | ||||||
| 08/18/2022 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 08/20/2021 | Alexion Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 06/21/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,092.00 | General |
| 04/23/2021 | Alexion Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 01/21/2021 | Biogen, Inc. | — | — | Cash or cash equivalent | $3,027.50 | Research |
| Study: A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 10/02/2020 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | — | Cash or cash equivalent | $400.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Patients with Amyotrophic Lateral Sclerosis • Category: Immunology | ||||||
| 05/20/2020 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Patients with Amyotrophic Lateral Sclerosis • Category: Immunology | ||||||
| 02/13/2020 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,137.50 | Research |
| Study: An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 02/13/2020 | Biogen, Inc. | — | — | Cash or cash equivalent | $787.50 | Research |
| Study: Long-Term Evaluation of BIIB067 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $3,938 | 3 |
| An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Biogen, Inc. | $3,238 | 2 |
| A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $3,028 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Patients with Amyotrophic Lateral Sclerosis | Alexion Pharmaceuticals, Inc. | $1,800 | 2 |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) | Alexion Pharmaceuticals, Inc. | $1,400 | 2 |
| Long-Term Evaluation of BIIB067 | Biogen, Inc. | $787.50 | 1 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | Biogen, Inc. | $700.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 175 | 222 | $58,405 | $11,469 |
| 2022 | 6 | 183 | 245 | $57,410 | $12,856 |
| 2021 | 6 | 166 | 210 | $44,590 | $11,653 |
| 2020 | 8 | 214 | 271 | $65,366 | $16,892 |
Total Patients
738
Total Services
948
Medicare Billing
$52,870
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 35 | 35 | $23,555 | $4,647 | 19.7% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2023 | 33 | 33 | $12,903 | $2,612 | 20.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 32 | 60 | $6,780 | $1,420 | 20.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 27 | 35 | $5,845 | $1,230 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 30 | $7,350 | $1,154 | 15.7% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 24 | 29 | $1,972 | $406.34 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 40 | 40 | $23,061 | $5,605 | 24.3% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2022 | 35 | 35 | $13,880 | $2,946 | 21.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 38 | 74 | $8,498 | $1,787 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 26 | $4,844 | $1,109 | 22.9% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 33 | 52 | $3,977 | $760.76 | 19.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 16 | 18 | $3,150 | $647.86 | 20.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $12,934 | $4,017 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 49 | $10,241 | $2,744 | 26.8% |
| 95910 | Nerve transmission studies, 7-8 studies | Facility | 2021 | 22 | 22 | $8,888 | $1,893 | 21.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 27 | 35 | $4,760 | $1,457 | 30.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 21 | 39 | $4,563 | $1,003 | 22.0% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Facility | 2021 | 22 | 36 | $3,204 | $538.28 | 16.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 81 | $16,929 | $4,350 | 25.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $12,488 | $3,834 | 30.7% |
| 99354 | Prolonged office or other outpatient service first hour | Facility | 2020 | 27 | 28 | $8,512 | $2,759 | 32.4% |
| 95910 | Nerve transmission studies, 7-8 studies | Facility | 2020 | 26 | 28 | $11,312 | $2,467 | 21.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 14 | $4,130 | $1,262 | 30.6% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2020 | 18 | 25 | $4,575 | $936.54 | 20.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 22 | 31 | $4,216 | $737.07 | 17.5% |
About Dr. Zachary Simmons, MD
Dr. Zachary Simmons, MD is a Clinical Neurophysiology healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790733814.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zachary Simmons, MD has received a total of $33,551 in payments from pharmaceutical and medical device companies, with $7,056 received in 2024. These payments were reported across 37 transactions from 6 companies. The most common payment nature is "" ($14,890).
As a Medicare-enrolled provider, Simmons has provided services to 738 Medicare beneficiaries, totaling 948 services with total Medicare billing of $52,870. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Neurophysiology
- Location Hershey, PA
- Active Since 05/04/2006
- Last Updated 12/29/2009
- Taxonomy Code 2084N0600X
- Entity Type Individual
- NPI Number 1790733814
Products in Payments
- RELYVRIO (Drug) $8,099
- Korlym (Drug) $3,088
- Ultomiris (Drug) $1,800
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.